Key Points
- Artiva Biotherapeutics SVP Heather Raymon sold 3,095 shares on May 19 at an average price of $9.01, totaling $27,885.95. After the sale, she still held 148,228 shares, and the transaction was tied to tax withholding from vested equity awards.
- The company’s recent results were weaker than expected, with Artiva reporting a quarterly loss of $0.95 per share versus the $0.88 consensus estimate. Analysts currently expect a full-year loss of $2.45 per share.
- Wall Street sentiment remains mixed but constructive overall, with several firms raising price targets sharply and the consensus rating sitting at “Moderate Buy.” The stock opened at $7.84, with a market cap of about $193.8 million and a 52-week range of $1.47 to $14.53.
Artiva Biotherapeutics, Inc. (NASDAQ:ARTV - Get Free Report) SVP Heather Raymon sold 3,095 shares of the business's stock in a transaction on Tuesday, May 19th. The shares were sold at an average price of $9.01, for a total value of $27,885.95. Following the completion of the sale, the senior vice president owned 148,228 shares in the company, valued at approximately $1,335,534.28. The trade was a 2.05% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Artiva Biotherapeutics Price Performance
Shares of ARTV opened at $7.84 on Thursday. The firm has a market cap of $193.80 million, a PE ratio of -2.21 and a beta of 2.86. Artiva Biotherapeutics, Inc. has a 1 year low of $1.47 and a 1 year high of $14.53. The stock's fifty day moving average price is $8.36 and its two-hundred day moving average price is $5.67.
Artiva Biotherapeutics (NASDAQ:ARTV - Get Free Report) last announced its quarterly earnings results on Friday, May 8th. The company reported ($0.95) earnings per share for the quarter, missing the consensus estimate of ($0.88) by ($0.07). Sell-side analysts anticipate that Artiva Biotherapeutics, Inc. will post -2.45 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Artiva Biotherapeutics
A number of hedge funds and other institutional investors have recently modified their holdings of the company. Dimensional Fund Advisors LP purchased a new position in shares of Artiva Biotherapeutics in the 1st quarter worth about $131,000. Sanctuary Advisors LLC purchased a new position in shares of Artiva Biotherapeutics in the 1st quarter worth about $139,000. Simplify Asset Management Inc. purchased a new position in shares of Artiva Biotherapeutics in the 1st quarter worth about $150,000. OMERS ADMINISTRATION Corp purchased a new position in shares of Artiva Biotherapeutics in the 4th quarter worth about $91,000. Finally, Marshall Wace LLP purchased a new position in shares of Artiva Biotherapeutics in the 4th quarter worth about $341,000.
Analysts Set New Price Targets
Several equities analysts have recently weighed in on the company. HC Wainwright lifted their price target on Artiva Biotherapeutics from $15.00 to $35.00 and gave the company a "buy" rating in a research report on Friday, May 8th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Artiva Biotherapeutics in a research report on Friday, April 24th. Wedbush boosted their target price on Artiva Biotherapeutics from $23.00 to $40.00 and gave the stock an "outperform" rating in a research report on Monday, May 11th. Needham & Company LLC boosted their target price on Artiva Biotherapeutics from $18.00 to $41.00 and gave the stock a "buy" rating in a research report on Tuesday, May 12th. Finally, Wall Street Zen cut Artiva Biotherapeutics from a "hold" rating to a "sell" rating in a research report on Sunday. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, Artiva Biotherapeutics has a consensus rating of "Moderate Buy" and a consensus price target of $39.00.
Check Out Our Latest Research Report on ARTV
Artiva Biotherapeutics Company Profile
(
Get Free Report)
Artiva Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of allogeneic “off-the-shelf” cell therapies for cancer. The company's proprietary platform leverages natural killer (NK) cells engineered to express chimeric antigen receptors (CARs) or other targeting modalities, with the goal of delivering potent anti-tumor activity while minimizing the safety and supply limitations associated with patient-derived (autologous) approaches.
Artiva's pipeline includes multiple lead product candidates designed to address both hematologic malignancies and solid tumors.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
